Notizie

Medindia4 h
Mitolyn Reviews 2025: How It Works, Pros & Cons, and Customer Feedback (Verified)
Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine
Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.
Neurology Advisor15 h
FDA Approves New Dosing Regimen for Kisunla in Alzheimer Disease
The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
PharmExec16 h
FDA Approves Label Update for Eli Lilly’s Kisunla to Reduce ARIA-E Risk in Early Alzheimer Disease Treatment
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
Becker's Hospital Review18 h
FDA OKs label change for Alzheimer’s drug
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
Zacks Investment Research on MSN20 h
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
MarketBeat on MSN20 h
Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
In today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...